HistAI

🚀 AI for Pathology Without Breaking the Bank! 🧬🔍 Think AI should be affordable? So do we! Our HIPAA-compliant platform CELLDX lets you analyze Whole Slide Images (WSI) for less than $1 per slide*. What’s included? ✅ 150GB of cloud storage ✅ Unlimited collaboration and presentation tools ✅ Advanced tissue labeling for custom AI development Take your pathology insights to the next level, without compromising on cost. Ready to see what’s possible? Try it out today! 👉 https://celldx.hist.ai *For Research Use Only. #DigitalPathology #ComputationalPathology #AffordableAI

🤖 👩🔬 Ready to rock the next three days at TechCrunch! Swing by Booth B7 to chat about speeding up cancer research, snag some cool stickers and sweets!

🎙️ Exciting news! Our very own Chief AI Scientist Dmitry Nechaev was featured in a Heather Couture, PhD podcast, sharing insights about Foundation Models in Pathology. Don’t miss out—listen now!

🎉 We are excited to share that our Chief AI Scientist, Dmitry Nechaev, presented at the 1st Annual Congress of the Asian Society of Digital Pathology (ASDP)! 🧑🔬🎤 Dmitry delivered an inspiring oral presentation titled "Hibou: A Family of Foundational Vision Transformers for Pathology." This cutting-edge research showcases our latest AI advancements, aimed at transforming the future of digital pathology. We would like to express our sincere gratitude to the Asian Society of Digital Pathology - ASDP and its President Junya Fukuoka and Vice-President Andrey Bychkov for providing us with this valuable platform and the opportunity to share our work with the community. 🙏 We are incredibly proud of our team’s work in pushing the boundaries of AI in healthcare! 🌍 #AI #DigitalPathology #ASDP #ComputationalPathology #FoundationModels #MedicalAI

Exciting news! 🎉 TechCrunch has recognized us as one of the top #StartupBattlefield companies in Life Sciences! We’re thrilled to be among the 200 startups showcasing at #TechCrunchDisrupt2024. This milestone means the world to us, and it's a testament to the passion and hard work we’ve put into building our company.

🎉 Please welcome two new SOTA open-source contributions in computational pathology! 🚀 We’re excited to introduce our latest breakthrough in computational oncology – CellViT-Hibou-L! This new cell segmentation and classification model builds on the strengths of the original CELLViT model and takes it to the next level. With the power of our foundation model, Hibou-L, we’ve managed to outperform nearly every benchmark. 🎯 CellViT-Hibou-L is available under the Apache 2.0 license with a non-commercial use clause, inheriting the original CELLViT license. But that’s not all! 💥 In even bigger news, Hibou-L is now available under the Apache 2.0 license with no restrictions – meaning free commercial use! We’re eager to see how it drives advancements in both research and industry. 🌍 🔗 Explore more: - CellViT-Hibou-L on Hugging Face: https://lnkd.in/en3mWpSG - Hibou-L on Hugging Face: https://lnkd.in/eukAdRbH - Updated paper: https://lnkd.in/ex7Uz_bC Let’s push the boundaries of what’s possible in medical imaging together! 💪 #AI #ComputationalPathology #DigitalPathology #CellSegmentation #GenAI #MedicalImaging

Is Open-Source AI the faster and more accessible cure for cancer? Groundbreaking models released for free! Leading startups such as Paige have released their foundation models under open source licenses. In my latest Hippogram, I delve into open spurce foundation models in healthcare. Digital Pathology startups like Paige, Bioptimus kaiko.ai and HistAI have started to release their foundation models as „open source“ and are setting new standards in medical AI. Even Microsoft is contributing to this novel open source ecosystem. There is still work to be done, to make these models commercially useful. Regulations and Open Source environments are challenging. It would also be great if our European University Hospitals would start releasing their data as commons. My insider network tells me that just the opposite is happening. Some directors of pathology institutes in Germany do not hesitate to give exclusive access to data to Taiwanese or US based AI companies in exchange for dollars. There is an urgent need for open licensing of the health data we consent to. Giving our consent for research, does not equal to giving our consent for exclusive commercial deals. This will keep startups back from developping open source alternatives, and allow others to set the new open standards. Link in the comments! thx to Falk Zakrzewski and Walter de Back from Katana Labs for the support.

Our Chief AI Scientist, Dmitry Nechaev, recently sat down with Piyush Mathur MD,FCCM,FASA,FAMIA and Rama Gullapalli, MD to discuss the development of Hibou, our first family of vision foundation models in pathology. Please enjoy a delightful session shedding light on the importance of foundation models and our specific experiences. Huge thanks to the BrainX AI community and Piyush Mathur MD,FCCM,FASA,FAMIA for the opportunity to discuss the promises and influence of foundation models in pathology. 🎬 Video: https://lnkd.in/eBZnJwVk

🔬 New Release: HistAI CELLDX Keratinocytic Lesions Suit* 👩⚕️ Today, in commemoration of #WorldCancerDay, we proudly unveil the "HistAI CELLDX Keratinocytic Lesions Suit," powered by a vast proprietary dataset of 6,353 whole slide images (WSIs), standing as one of the largest datasets in the field, as far as our knowledge goes. Validated on 1,459 slides, our algorithm promotes precision and reliability in real-world scenarios, contributing to the global fight against cancer and supporting the #CloseTheCareGap initiative. 💙👩⚕️👨⚕️ In line with our #openaccess policy, we are thrilled to offer free evaluations of this groundbreaking AI widget. Anyone can experience its capabilities firsthand by checking it out now at https://celldx.hist.ai 🌍✨ This release marks another milestone in our commitment to delivering cutting-edge products to the global community of pathologists. Let's continue to unite, innovate, and #closethecaregap together! 💙🤝 *For research use only. Not for primary diagnosis. #aimedicine #ComputationalPathology #healthtech #innovation #AIForGood #MedicalAdvancements #DigitalPathology #Dermatopathology #DermPath #HIMSS2024